The Seattle Genetics Regulatory Affairs Fellowship is a one-year, experiential program at Seattle Genetics based in Bothell, WA. The purpose of this program is to prepare PharmD fellows for career opportunities in pharmaceutical Regulatory Affairs – Labeling by providing in-depth biopharmaceutical industry experiences and enhancing clinical knowledge.
The Seattle Genetics Regulatory Affairs Fellowship provides a unique opportunity for a PharmD graduate to gain training and hands-on experience in a specialized area of Regulatory Affairs – Labeling. The fellow will work closely with the Regulatory Affairs – Labeling Lead on marketed and development-stage products. The fellow will have the opportunity to interact cross-functionally with a broad group of team members and key stakeholders, including: Clinical Development, Drug Safety, Clinical Pharmacology, Commercial, Legal, and Medical Affairs.
The fellow will support ADCETRIS® (brentuximab vedotin), an antibody-drug conjugate (ADC) directed to the CD30 surface antigen on cells using Seattle Genetics' proprietary ADC technology. The fellow will also support Seattle Genetics’ pipeline programs, including late-stage agents enfortumab vedotin and tucatinib.
Participate in the development of company positioning for product labels
Create labeling content in support of NDA, BLA, and global marketing applications
Conduct competitive label intelligence research
Coordinate label responses and updates during label negotiations with Health Authorities
A Doctor of Pharmacy (PharmD) degree from an ACPE accredited institution
Analytical, planning and organizational skills
Possess good communication skills, including oral, written and presentation
Self-motivated, energetic, able to work and learn independently
Ability to thrive in a fast-paced, dynamic environment
Good medical and scientific judgement, attention to detail, and excellent interpersonal skills, including ability to work effectively cross culturally and cross functionally
Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.
Application deadline is Monday, November 27th, 2019.
Letters of Recommendation are not required with application and are only required upon request.
Internal Number: 4
About Seattle Genetics
Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is approved for the treatment of multiple CD30-expressing lymphomas.
Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer use our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.